AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal
Executive Summary
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
You may also be interested in...
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Gilead Dives Into Protein Degradation With Nurix Pact
Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.
Vertex Targeting Protein Degradation In $1bn Kymera Deal
Vertex and Kymera will use insights into the ubiquitin-proteasome pathway, for sending unwanted proteins off to recycling, to discover new drug candidates.